Project Grant R01AI187165
Award Date
8/1/25
Completion Date
7/31/29
Dollars Obligated
$3M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Pensilvania, EE. UU.
Similar Awards
This federal Project Grant award, valued at $312,000.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award will support research conducted by the University of Texas Health Science Center at Houston (UTHealth) to develop a single-cell resolution understanding of pathogenesis and antibiotic tolerance in Staphylococcus aureus infections. The research aims to explore the...
The federal Project Grant award R21AI188434, totaling $226,253.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research conducted by The Washington University, a private research institution located in Missouri, to study the modulation of neutrophil-endothelial interactions by the ADAM10 protein and its impact on Staphylococcus aureus infection. The goal is to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $474,363.00 to Rowan University to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The goal is to create new peptide molecules that mimic daptomycin's key mechanisms of action, such as calcium binding and lipid membrane disruption, while improving resistance to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $231,700 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Texas A&M University System Health Science Center to develop novel biologics for treating Staphylococcus aureus (S. aureus) infections, including antibiotic-resistant strains like methicillin-resistant S. aureus (MRSA). The research aims to characterize the binding and neutralization properties of engineered DARPin proteins against...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,144,714 to the University of Illinois to conduct research aimed at discovering novel antibiotics for gram-negative pathogens. The primary goals are to identify physicochemical traits that allow antibiotics to evade efflux pumps in E. coli, P. aeruginosa, and A. baumannii, and then apply this knowledge to develop at...
This federal Project Grant award of $254,478 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify mechanisms of resistance to pathogen-specific antibacterial antisense compounds and develop strategies to overcome them. The award recipient, The University of Texas Southwestern Medical Center, will investigate resistance to these novel antibacterial compounds called...
This Project Grant award of $2,841,668.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research focused on understanding how the bacterial enzyme SagB in Staphylococcus aureus (S. aureus) modulates the host immune response and promotes infection. The key goals are to determine how SagB-modified peptidoglycan is recognized by immune cells, investigate the mechanism of SagB-dependent IL-1β...
This federal Project Grant award of $3,125,627.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop new therapeutic strategies that promote enhanced anti-microbial immune responses. The key objectives are to: 1) optimize inhibitors of the STS-1 phosphatase enzyme, which acts as a negative regulator of immune signaling pathways; 2) elucidate the intracellular activities of STS and identify promising inhibitory...
This Project Grant award of $427,625.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by Washington University to discover novel anti-biofilm agents derived from bacteriophages. The goal is to develop alternative therapies for treating biofilm-associated infections, which are a major challenge for pathogens like Pseudomonas aeruginosa. The research will isolate phages that can overcome biofilm barriers,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA program 93.855 "Allergy and Infectious Diseases Research," is providing $813,373 to Rutgers, The State University of New Jersey to conduct research on developing new classes of pyrazinoic acid prodrugs against pyrazinamide-resistant Mycobacterium tuberculosis. The goal is to characterize the diverse set of Mycobacterium tuberculosis amidases and the compound structures...